permax

基本解釋

Permax was approed in 1988 for Eli Lilly and Company as an adjunctie therapy with leodopa in Parkinson's disease. alular heart disease was first described in association with pergolide in 2002.
Permax是伊萊利利公司於1988年獲得批準(zhǔn)的、作爲(wèi)輔助治療葯物與左鏇多巴用於帕金森氏癥的治療。
In 2003, FDA asked Lilly to add alulopathy (abnormality of cardiac ales) to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was sent by Lilly.
首次關(guān)於培高利特與瓣膜性心髒疾病相關(guān)的報(bào)道是在2002年，2003年FDA要求伊萊利利公司在培高利特標(biāo)簽的警告部分添加心髒瓣膜疾病的警示語，同時(shí)該公司發(fā)出了“致健康從業(yè)者信”。